An herbal medicinal substance, Crataegus Extract WS?1442, safely extends the lives of congestive heart failure patients already receiving pharmacological treatment for the disease, according to a study presented today at the American College of Cardiology?s 56th Annual Scientific Session.
Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.
The costs due to complications from preterm birth are staggering. In Canada, outlays for specialized care of surviving preterm infants are estimated to be almost $2 billion per year.
Schering-Plough Corporation (NYSE: SGP) announced that it has entered into an agreement with Merck & Co., Inc. to commence development of an ezetimibe and atorvastatin combination product.
CSL Limited announced results from a study published in the Journal of the American Medical Association that suggest infusions of a novel new drug, CSL-111, to acutely raise HDL (“good” cholesterol) levels, may reduce the amount of plaque in the coronary arteries of patients with a recent episode of acute coronary syndrome (ACS).
Women who take low to moderate doses of aspirin have a reduced risk of death from any cause, and especially heart disease-related deaths, according to a report in the March 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
For patients with severe chronic heart failure, known as stage D or chronic decompensated heart failure (CDHF), hospitalization is frequent and treatment options are limited.
A combination of two medicines that act against the effects of the enzyme renin are more effective in lowering blood pressure than either of the medicines alone, according to a study presented today at the American College of Cardiology?s 56th Annual Scientific Session.
GlaxoSmithKline (GSK) announced that its new, novel topical antibiotic ALTARGO? (retapamulin ointment, 1%) received a positive opinion from the European Committee for Human Medicinal Products (CHMP) for the treatment of impetigo and infected small lacerations, abrasions or sutured wounds.
An international study using ultrasound technology has found that the most potent cholesterol-lowering drug is also effective at halting early changes in the blood vessels that can lead to atherosclerosis.